Post-Marketing Surveillance of MabThera Subcutaneous in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Trial Profile

Post-Marketing Surveillance of MabThera Subcutaneous in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top